Emtricitabine/tenofovir alafenamide

Emtricitabine/tenofovir alafenamide (also known as FTC/TAF) is a fixed-dose combination of antiretroviral drugs used in the treatment and prevention of HIV/AIDS. It is a combination of two active ingredients: emtricitabine and tenofovir alafenamide.

Composition[edit | edit source]

Emtricitabine/tenofovir alafenamide is composed of two antiretroviral drugs. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), which works by blocking the action of an enzyme called reverse transcriptase, thereby preventing the virus from multiplying in the body. Tenofovir alafenamide is a prodrug of tenofovir, which is also an NRTI.

Uses[edit | edit source]

Emtricitabine/tenofovir alafenamide is used in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults and pediatric patients. It is also used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in individuals at high risk.

Side Effects[edit | edit source]

Common side effects of emtricitabine/tenofovir alafenamide include nausea, diarrhea, headache, and fatigue. Serious side effects may include kidney problems, liver problems, and bone loss.

Interactions[edit | edit source]

Emtricitabine/tenofovir alafenamide can interact with other drugs, including certain antiviral drugs, antifungal drugs, and antibiotics. It is important to inform healthcare providers of all medications being taken to avoid potential drug interactions.

Dosage[edit | edit source]

The dosage of emtricitabine/tenofovir alafenamide is determined by the healthcare provider and depends on the individual's health condition, other medications being taken, and response to treatment.